Analyst Stock Recommendations For Opko Health, Inc. (OPK), The Boeing Company (BA)
Following the acquisition, the chief executive officer now owns 3,068,951 shares in the company, valued at approximately $22,986,442.99. The share price has moved backward from its 20 days moving average -2.24% and negatively from its 50 days moving average -3.34%.
On Thursday, April 6th, Phillip Md Et Al Frost bought 28,600 shares of Opko Health stock. The shares were purchased at an average price of $7.58 per share, with a total value of $212,240.00. After $-0.04 actual earnings per share reported by Opko Health Inc. for the previous quarter, Wall Street now forecasts 25.00% negative EPS growth.
On Friday, March 31st, Phillip Md Et Al Frost purchased 1,800 shares of Opko Health stock. Analysts set a 12-month price target of $5.83 a share. There may be various price targets for a stock.
On Wednesday, March 29th, Phillip Md Et Al Frost acquired 9,200 shares of Opko Health stock. According to these analysts, the Low Revenue Estimate for Opko Health, Inc.is 287.3 Million and the High Revenue Estimate is 330.1 Million. The company is estimating to achieve earnings per share (EPS) growth of 26.00% in this year and the earnings per share (EPS) growth expected to be 180.00% in the next year. Raymond James Financial Services Inc accumulated 51,264 shares or 0% of the stock. The company maintains price to book ratio of 1.43 vs.an industry average at 5.08.
OPKO Health, Inc.is a healthcare company. Its price to free cash flow for trailing twelve months is 504.39 and Current ratio for most recent quarter of 1.80. The business had revenue of $275.50 million for the quarter, compared to analysts’ expectations of $310.82 million.
04/30/2015 – Opko Health Inc was upgraded to “hold” by analysts at Zacks.
Several sell side analysts reviewed their recommendations on Opko Health, Inc. (OPK) to Buy with no specific Price Target on 12/30/16. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & global trademark and copyright legislation.
On Tuesday, March 28th, Phillip Md Et Al Frost bought 3,600 shares of Opko Health stock.
A number of research firms have recently weighed in on OPK. Standpoint Research restated a “buy” rating and issued a $14.00 target price on shares of Opko Health in a research note on Sunday, March 5th.
Now the shares of Opko Health, Inc. $16,214 worth of Opko Health Inc. Guggenheim initiated coverage on Opko Health in a research note on Tuesday, March 14th. Finally, TheStreet lowered shares of Opko Health from a “c-” rating to a “d+” rating in a report on Wednesday, February 1st.
Among 6 analysts covering Aduro Biotech (NASDAQ:ADRO), 3 have Buy rating, 1 Sell and 2 Hold. Tracking the stock price in relation to moving averages as well as highs and lows for the year might assist with evaluating future stock performance.
Hedge funds have recently added to or reduced their stakes in the stock. Piedmont Investment Advisors LLC purchased a new position in shares of Opko Health during the third quarter worth $622,000. Bank of Montreal Can raised its position in shares of Opko Health by 1.4% in the first quarter. Finally, Envestnet Asset Management Inc. increased its stake in shares of Opko Health by 23.6% in the fourth quarter. Formidable Asset Management LLC now owns 11,638 shares of the company’s stock worth $108,000 after buying an additional 1,096 shares during the last quarter. With an institutional ownership near 75.3%, it carries an earnings per share ratio of 7.66.
10/16/2015 – JP Morgan began new coverage on Opko Health Inc giving the company a “overweight” rating. The Company operates through two segments: diagnostics and pharmaceutical. Pharmaceutical consists of the pharmaceutical activities in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.